Tilray Announces Successful Medical Cannabis Harvest In Portugal; Provides Update On European Operations

CANADA: Tilray, a global leader in cannabis research, cultivation, production and distribution, announced that its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. has completed a successful harvest of medical cannabis at the Company’s European Union (EU) Campus in Portugal.

Tilray_LogoTilray’s EU Campus in Portugal is a multi-faceted production facility that includes indoor, outdoor and greenhouse cultivation sites, as well as research labs, processing, packaging and distribution sites for medical cannabis and cannabinoid-derived medical products. To date, Tilray has invested approximately €20 million in the facility, which totals nearly 250,000 square-feet with additional room to expand. Tilray’s EU Campus also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray’s EU Campus currently employs 100 people, and that number is expected to double by the end of 2019, with production ramping up and multiple harvests anticipated in the coming months.

“Our harvest in Portugal is an exciting milestone for the company as we continue to build our multinational supply chain of high-quality medical cannabis,” said Sascha Mielcarek, Managing Director, Europe. “We look forward to utilizing the capacity of Tilray Portugal to supply the medical cannabis market in Europe as we expand our operations.”

Tilray was the first licensed medical cannabis producer to successfully import medical cannabis products into the EU and the first licensed medical cannabis producer in North America to obtain Good Manufacturing Practice (GMP) certification in accordance with the European Medicines Agency’s (EMA) standards. Tilray has established sales and distribution arrangements to distribute medical cannabis through major pharmaceutical distribution channels throughout Germany and the European Union. The Company has also formed a global alliance with Sandoz AG, a worldwide leader in generic pharmaceuticals and biosimilars and a part of Novartis group, to increase availability of high quality medical cannabis products around the world in jurisdictions where regulations permit.

In addition to its EU Campus in Portugal, Tilray currently operates multiple state-of-the-art production and processing facilities in Canada. Tilray looks forward to hosting an official ribbon-cutting event at its EU Campus in Portugal later this spring.

Cura Partners Enters European Market With Plata Wellness To Distribute Select CBD Brand

UNITED KINGDOM: Cura Partners, one of the largest cannabis and hemp-based CBD consumer products companies in the world, is officially entering the European market (EU) through a distribution agreement with Plata Wellness.

CuraThe agreement allows Cura’s Select CBD products to be available direct to consumers in legal markets across Europe via the website www.selectcbd.eu. Cura has appointed Plata Wellness Limited (Plata) to assist with its entry into the EU. In addition to Plata’s role as Cura’s inaugural overseas distributor, Plata is also providing a number of other services including order fulfillment, payment processing, and in the future, licensing and manufacturing. This partnership begins with the introductions of Select’s CBD disposable vaporizer cartridges but will, over time, add other legal consumer products including tinctures, gel caps and muscle rubs.

“Cura’s decision to move into Europe is in direct alignment with the company’s mission to be the leading provider of cannabis oil to consumers and brands in legal U.S. and international markets,” said President and Chief Executive Officer Cameron Forni. “I’m proud of the team that made this possible, and look forward to partnering with Plata Wellness to get the Select CBD brand into the hands of consumers across Europe.”

Europe is home to more than 741 million people, more than double the combined population of the United States and Canada. When trying to extrapolate these numbers to account for the potential demand in Europe’s much larger population, there is a crystal-clear reason why established cannabis companies in the United States are now turning their attention to Europe.

“We are delighted to have partnered with Cura, the market leading company in this sector. We are excited to work together to bring the Select brand to prominence in Europe and to supply consumers with these award-winning products,” said Jon Robson, Managing Director at Plata Wellness Limited.

Consumers in the United Kingdom can purchase Select CBD Blends vape pens online at www.selectcbd.eu with additional products coming soon.

Aphria Introduces First Cannabis Strains To Be Produced In Europe With Export To Danish Partner Schroll Medical

CANADA: Aphria Inc. completed its first transfer of plant cuttings from four of the Company’s cannabis strains to Denmark-based Schroll Medical, as part of the Company’s previously announced Strategic Partnership with Schroll. The shipment was completed under permits issued by the relevant health authorities, including an export permit from Health Canada, an import permit from the Danish Medicines Agency and a phytosanitary certificate from the Canadian Food Inspection Agency.  

aphria logo“We are pleased to introduce the first four Aphria strains to be produced in Europe, through our strategic alliance with Schroll,” said Hendrik Knopp, Managing Director of Aphria Germany, who is overseeing the Partnership on behalf of Aphria and Schroll. “This marks another important milestone for Aphria as we extend our leadership position in the European market, and it gives me joy to be able to say today that we literally have a good thing growing in Europe.”  

As previously announced, Aphria will handle the worldwide distribution of medical cannabis produced by the Partnership, which is anticipated to be made available to markets across Europe as medical cannabis markets develop. Aphria plans to complete a second shipment of additional strains to Schroll in the coming months.

New Report Details Growth Of Global Cannabis Market to 2023

IRELAND: ResearchAndMarkets.com has released the “Cannabis Market by Product Type (Flower, Concentrates), Compound (THC-Dominant, CBD-Dominant, and Balanced THC & CBD), Application (Medical and Recreational), and Region (North America, South America, Europe, and Row) – Global Forecast to 2023” report.

Among the highlights:

Growing medicinal application of cannabis is expected to drive the overall growth of the cannabis market

  • The cannabis market size is expected to grow from USD 10.3 billion in 2018 to USD 39.4 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 30.7% during the forecast period.
  • The cannabis market is driven by various factors such as the growing medicinal application of cannabis and the increasing legalization of cannabis. However, a complex regulatory structure for the use of cannabis can hinder the growth of the market.
  • The concentrates segment is the fastest-growing segment in the cannabis market, by product type. This is due to their ease in usage and their versatility in the method of delivery, such as dabbing, ingestible oils, and tinctures. Also, along with ingestion, concentrates can offer cleaner, smoother, and less-odiferous hits than flowers. Concentrates are being increasingly opted for over flowers, as these as more potent in nature. The potency of concentrates could also be modified as per requirement and usage, to evoke a higher consumer likeability.
  • The THC-dominant segment is projected to hold the largest share and grow at the highest CAGR during the forecast period. The dominance of this segment is majorly attributed to the fact that THC is the psychoactive substance in cannabis products and is responsible for head high feeling. Even though high THC content is better known for its mind-altering euphoria, it has important medical benefits and is considered effective in relieving nausea, appetite loss, and insomnia.
  • The market in this region is primarily driven by the growth in the US and Canadian markets. The market in this region is driven by the increasing legalization of cannabis for both medical and recreational purposes all over North America and the increasing awareness among consumers regarding the health benefits of cannabis.

 

Europe’s Legal Cannabis Market Is A €56 Billion Opportunity

UNITED KINGDOM: A new report from industry advisors, Prohibition Partners, suggests that Europe will become the largest legal cannabis market in the world once all countries have introduced legislation and regulation over the next five years.

Cannabis is set to become the major global industry of the post-digital generation. It will drive economic and employment growth as well as having a significant impact on a wide range of social issues.

The impressive financial performance of North American cannabis companies is already drawing in institutional investors – even before US federal legislation.

However, Europe is quickly catching up with a record number of countries introducing medical cannabis legislation already this year. Most governments understand the medical and tax benefits so are moving fast to position correctly for this opportunity. Buoyed by a shift in legislation and ground breaking returns, the European cannabis industry represents a very unique and rewarding opportunity.

The European Cannabis Report™ (2nd Edition) explores the complex regulatory environment while providing a detailed analysis of 15 key markets across the medical, recreational and industrial sectors.

 

Tilray Receives License to Produce Medical Cannabis In The European Union

Company Announces €20 Million Investment to Build EU Campus and Begin Operations this Year

PORTUGAL: Tilray has announced plans today to invest up to €20 million in a European Union Campus after receiving licenses from the Government of Portugal to import cannabis genetics and to cultivate cannabis for medical purposes.

“Tilray’s EU Campus is another strategic milestone as we aim to build the world’s most trusted and admired medical cannabis brand,” said Brendan Kennedy, Chief Executive Officer of Tilray. “For the past two years we’ve been working hard to find the right location for cultivation, processing, and research facilities to serve rapidly growing demand for high-quality medical cannabis products in Europe. Portugal has the ideal climate to cultivate cannabis, a highly-skilled health care workforce, and a vibrant research community. It’s more environmentally-friendly and cost-effective to supply European patients from Portugal than from northern climates.”

State-of-the-Art EU Campus Will Begin Operations This Year

To establish the EU Campus, Tilray will invest up to €20 million through its affiliate, Tilray Portugal Unipessoal Lda., in multiple facilities located in and around the BIOCANT Research Park in Cantanhede, Portugal. The EU Campus will include indoor, outdoor, and greenhouse cultivation sites, as well as facilities to process, package, and distribute medical cannabis and cannabinoid-derived medical products. As a part of the BIOCANT biotechnology and life sciences research park, the EU Campus will serve as a hub supporting Tilray’s clinical research and product development efforts across Europe.

Tilray is currently leasing laboratory and indoor cultivation space within BIOCANT. This month, Tilray will begin construction on a greenhouse and a processing facility on property purchased by the company. Phase one of the project, which is expected to be complete by spring of 2018, includes an indoor laboratory and genetics bank, outdoor cultivation sites, a 10,000 m2 greenhouse, and a 1,500 m2 processing facility. Subsequent phases, which are expected to be completed by 2020, will add 15,000 m2 of greenhouse cultivation space and another 1,500 m2 for processing. Over the next three years, the project is expected to create 100 direct jobs, including highly-skilled positions.

EU Campus Accelerates Tilray’s Global Expansion Strategy

In response to considerable unmet need for high-quality medical cannabis, Tilray is investing aggressively to expand its operations around the world. In addition to Tilray Portugal Unipessoal Lda., Tilray has wholly-owned subsidiaries in Germany (Tilray Deutschland GmbH), Canada (Tilray Canada Ltd.), and Australia and New Zealand (Tilray Australia and New Zealand Pty. Ltd.).

Tilray has a proven track record as a global pioneer in the medical cannabis industry:

  • In 2014, Tilray was one of the first companies to be federally-licensed to cultivate, process and distribute medical cannabis in Canada.
  • In December 2016, Tilray became the first medical cannabis licensed producer in North America to be GMP-certified in accordance with the European Medicines Agency’s (EMA) Good Manufacturing Practice (GMP) standards. GMP certification is the most rigorous standard that manufacturers of medical products must meet in their production processes. In countries new to medical cannabis, GMP certification provides regulators and health care providers with certainty that Tilray products are a safe and smart choice.
  • In 2016 and 2017, Tilray launched clinical research partnerships with world-leading hospitals and universities to study the safety and efficacy of medical cannabis for a diverse range of conditions, including post-traumatic stress disorder (PTSD), chronic obstructive pulmonary disorder (COPD), pediatric epilepsy, and chemotherapy-induced nausea and vomiting (CINV).
  • Throughout the last year, Tilray became the first company to legally export medical cannabis products from North America to the European Union, Australia, New Zealand, and South America. Tilray products are currently available in six countries spanning four continents.

By the end of 2017, Tilray expects to export medical cannabis products to five more countries. The company also anticipates announcing federal licenses from additional countries, as well as research partnerships in Portugal, Germany, and other countries around the world.

Tilray Portugal Timeline

Tilray executives first visited Portugal in 2015. After conducting extensive due diligence, consultation with stakeholders, and a country-wide property search, Tilray reached a Memorandum of Understanding with the Government of Portugal in October 2016. Tilray Portugal Unipessoal Lda. was incorporated in March 2017. The company purchased property in Cantanhede in July 2017.

 

'First Ever' Bill Proposes Legal Cannabis In France

FRANCE:  France is no Amsterdam when it comes to marijuana laws.  In fact, it has some of the toughest possession statutes in Europe,  but a first of its kind bill proposed this week could change that. The lawmaker behind the legislation tells The Local why marijuana should be legalized in France.

People smoking a joint in France face a maximum penalty of a year behind bars and a €3,750 fine for the first offence, yet 13.4 million French people admit to sparking up at least once in their life. Even France’s top cop, Interior Minister Manuel Vallls, said in a recent interview, he’d tried it “maybe once.” [Read more…]

Cannabis To Be Consumed Legally In Public Next to Parliament

UNITED KINGDOM: The national organization for cannabis law reform, will be holding a static demonstration close to the Houses of Parliament on the 9th October 2013, commencing around midday.

The purpose will be to protest the discriminatory laws whereby a medical cannabis patient from Europe is legally entitled to consume their herbal cannabis medicine in the UK, but a UK citizen is not. [Read more…]

Cannabis Cafes Could Set Up Shop In Berlin

GERMANY: When Monika Herrmann took office as Berlin Kreuzberg’s mayor in August, she made cannibis legalization a priority. It’s a topic igniting controversy in the city’s capital, especially with German federal elections set for Sept. 22. [Read more…]